US Edition
News from Pharmacy Times
We’ve assigned a rating of Unknown factuality to Pharmacy Times. You can read more about how we’ve determined Pharmacy Times’s credibility and reliability as a news source here: https://ground.news/rating-system.
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Pharmacy Times News
United States · United States/PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and...See the Story
DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
42% Center coverage: 7 sources
DiabetesNovo Nordisk A/S (NYSE:NVO) on Monday shared headline results from the REIMAGINE 2 phase 3 trial from the global REIMAGINE clinical trial program. CagriSema for weight management was submitted to the U.S. Food and Drug Administration (FDA) in December 2025 based on the REDEFINE 1 and REDEFINE 2 pivotal trials. Trial Data REIMAGINE 2 was a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination…See the Story
Novo Nordisk's Next-Gen Combination Drug Beats Semaglutide in Weight Loss and Blood Sugar Control - Novo Nordisk (NYSE:NVO)
80% Center coverage: 5 sources
